CAR-T cells could overcome trastuzumab resistance and target tumours that express ERBB2 at moderate levels (e.g., osteosarcoma, glioblastoma, and medulloblastoma) that commonly escape trastuzumab treatment [60]. This evidence concerns the gene ERBB2 and medulloblastoma.